Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

BusinessWire_EN 
0 0 03.01.22
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
 

Regulatory News:

MaaT Pharma (EURONEXT: MAAT - the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that its CEO and co-founder, Hervé Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 am EST/1:00 pm CET on Monday, January 10, 2022.

A replay of the presentation will also be made accessible in the investors’ section of the company’s website at www.maatpharma.com from Friday, January 14, 2022 and for 90 days after the event.

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.

The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005329/en/

Maat Pharma S.a. Stock

€6.90
-3.090%
Heavy losses for Maat Pharma S.a. today as the stock fell by -€0.220 (-3.090%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Maat Pharma S.a. stock is not clear.
As a result the target price of 10 € shows a positive potential of 44.93% compared to the current price of 6.9 € for Maat Pharma S.a..
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!